

Wheeler Bio

Solving for Speed in Translational CMC

Jesse McCool, Ph.D.

Co-Founder and CEO at Wheeler Bio

May 2023

Drug Development Lifecycle Needs to Improve

Next-gen biologics could address the world's remaining disease but face outdated provider paradigms

The cost to bring a drug candidate from research and discovery to regulatory approval is approximately $2.6B (capitalized cost, 2013 dollars). Of the $2.6B figure, $1.4B represents out-of-pocket cost and $1.2B is time cost. Studies completed by other researchers have estimated similar figures, with capitalized cost ranging between $1-$3B. Typically, total cost to bring monoclonal antibodies and recombinant proteins to market is much lower, averaging around $1.3B.

BOTTLENECKS

12+ years

EXPENSIVE



$2.6B

FRICTION



~500 days

of tech transfer delays

Ref: DeMasi – Tufts Center for Study of Drug Development

Gap in Early-Stage Development Related to CMC

To minimize the risk of later-stage failure, several key CMC areas must be considered in early development

Approximately six out of 100 molecules make it from the discovery stage to phase 3 clinical trials. The attrition of the other 94 molecules represents a gap in early-stage development that could be related to chemistry and manufacturing control (CMC) issues. CMC activities include the establishment of manufacturing processes and product characteristics, as well as defining product testing methods to ensure that the product is safe, effective, and consistent between batches. To minimize the risk of later-stage failure, several key CMC areas mush be considered in early development.



Critical Areas of Risk Consideration for Early-to-Late-Phase Transition
Cell Line Performance
API CQAs
Raw Materials
Formulation
Manufacturing Process Design
Analytical methods
Development history

Gap in Early-Stage Development Related to Capital

Seed : Used for the **lead optimization** stage
- Perform *in vitro* mechanistic validation (POC in animals)
- Generate early *in vivo* data showing therapeutic rationale in a key indication
- The investors need to see that there is a development path and a competitive advantage within the landscape

Series A : Used for **IND enabling studies**
- Demonstrate robust *in vivo* data that shows a benefit over standard-of-care or competitor with a clear clinical development plan and timelines to human data
- Finish IND enabling studies as the investor wants this round to get close to the clinic and build out a team to execute the plan
- Size of round depends on team and modality/tech

Series B : Used to get to **human POC** in patients with the disease
- Investor needs to see an exit like IPO or acquisition based on successful clinical data
- Investor needs confidence the money is not just paying for CMC and scale but that POC will be achieved even with some expected delays – so buffer funds needed
- Size of round depends on team and modality/tech and size of buffer
-

Series C/Crossover : Used to take through to pivotal studies
- definitive exit plan

Ref: GSL CMC Consulting – Steve Monks



Burn rate = $150K/month

$20-$50MM

2-3 years to FIH

Developers Take On Most of the Early CMC and Business Risk

Providers typical cannot share risk due to business design which leads to poor customer experience

Figure 1.4-C
Benefit- or Risk-Sharing Arrangement



HighTech Business Decisions

How to Solve for Translational Gaps?

Align CMC with Capital

- There is a gap in the drug development process between discovery and early development
- Developers getting stuck with too much technical risk at end of discovery
- Developers experiencing loss of momentum in fundraising between seed and Series A
- CROs have tried to forward integrate but it's too capital intensive to add GMP



Wheeler Shifting the CDMO Paradigm to Fill Gap

CDMO inside venture studio for improved capital and resource alignment

Agility
Ease-of-Access
Speed
Freedom
Innovation



Value Proposition

A new CDMO paradigm built to take on the translational space

Agility
Focused and purpose-built enterprise enables new tier in customer experience

Ease-of-Access
Thoughtful alignment of services to match fundraising process

Speed
Rapid pool-based workflows enable speed-to-clinic

Freedom
Open-source platform for de-risking scale-up and tech transfers



Innovation
Tech stacked with integrated digital solutions for de-risking the scale-up manufacture

echo









Wheeler Bio:
->Agile, Boutique CDMO
->Inside Venture Studio
->De-risk ROI

Solving for Translation

Experienced Leadership

Aligned Culture

Technology Stacked

Compressed Workflow

GMP Go-Live: Q3 2023



Wheeler Bio

Purpose Built

Wheeler Co-Founder Jesse McCool

- Scientist by training with 20+ years in development
- Ph.D. UMASS & Postdoc Dartmouth
- Mascoma | Lonza | Cytovance | Wheeler
- Joined Cytovance in 2013 and helped grow company by 50% in 2 years
- Sold to Shenzhen Hepalink Pharmaceutical Group in 2015 and stayed on to drive growth. Became CEO in 2020 and led HK IPO ($529MM)
- JV Partner with Alloy Therapeutics (Waltham)

Wheeler Co-Founder Christian Kanady

- Entrepreneur from Oklahoma City and founding partner of Echo with $1.3B in AUM (PE/VC)
- B.S. University of Oklahoma
- Chesapeake | Echo Energy | Echo | Wheeler
- Investor in life science, technology, entertainment, national security, and real estate
- Philanthropist and long-term partner in community development, education, social services, youth athletics, and music, and the Arts
- JV Partner with Alloy Therapeutics (Waltham)



Echo Is Oklahoma City Based Venture Studio ($1.3B AUM)



"The Ziggurat"

Echo Building an “Echosystem” - Connective Capital

Connective Capital + Antibodies + Rapid CMC Concepts + Local Clinic + Sick OK = SPEED to Finance, SPEED to Clinic

Day 1 August 17, 2020



Shared Vision: Oklahoma City and its collective stakeholders – including capital- can work together to accelerate the biological drug development process

The First 180 Days of Wheeler

2020

2021

Build Team, Cover Cost with COVID Testing, Plan CDMO

Model CDMO, Pitch Deck, Initiate Seed

Sep 2020

Sep - Nov

October

Oct- Aug

Jan-Mar

May



Training at Phosphorus

9-11 2020

Recruited Team

CLIA License

Lab build and validation

Launched product

Wheeler Labs

CDMO Ideation

Colcord Session

Seed Round Start

Wheeler's Vision, Mission, Core Values

Vision

To transform the CDMO industry for the benefit of patients around the world

Mission

To accelerate the translation of drug discoveries into clinical impact for our clients

Integrity: We strive to be authentic and operate at the highest ethical and quality standards.

Embrace New Ideas: **We seek innovative solutions from each other and leverage superior technologies to add value.**

Dedication: We wholly commit to a particular course of thought or action and follow through until results are achieved.

Respect for Others: We go out of our way to listen and to be accepting of the experience of others.

Efficiency: We strive to continuously improve our processes, facilities, services, and systems by challenging status quo and eliminating waste.

Play to Win: We give our all to help ensure victory for our clients and to give the patients they serve hope.

Wheeler's Vision, Mission, Core Values

Vision

To transform the CDMO industry for the benefit of patients around the world

Mission

To accelerate the translation of drug discoveries into clinical impact for our clients

Embrace New Ideas: We seek innovative solutions from each other and leverage superior technologies to add value.

Novel Operating Model

Hub-and-spoke concept to better connect cost-advantaged Oklahoma with drug developers

ATUM 2022

Newark, CA

Alloy 2021

ltham, MA

CRO 2023

South San Francisco, CA

$35MM Award for Biomanufacturing Infrastructure

Scalable Equipment Plan

From benchtop to FIH to pivotal studies, reliably and predictably

Ambr® 15	Ambr® 250	BioFlo	HyPerforma™	DynaDrive™	Single-Use Bioreactor Line	
15 mL	250 mL	3L /10L /40L	50L	500L	3000L	5000L

Clinical Development	Pilot/Clinical	Clinical/Commercial
Series Seed	Series A	Series B

Platform Process - Portable CMC™ - Late Phase Process for FIH

Enhances the baseline process, product and CMC knowledge and understanding



Digital Twins

Support better manufacturing processes in faster timelines



Michael Sokolov

DataHow

Digital Twins to

- ***Improve predictability***
- ***Improve insights***
- ***Support* better manufacturing processes in faster timelines**

Challenges In Standard Processing, Digitalization, and Prediction

Biology is difficult to model and data points are few (too expensive)

- Lack of N's at scale
- Huge complexities with biological based systems – need a variety of tools to solve technical issues
- Process scientists are good practitioners of equipment/process but lack data science expertise
- Expensive data points

Thousands of interactions

Cells



Proteins



Hundreds of interactions

Process Development



Manufacturing



The Prediction Problem

Data is Expensive- Each Experimental Run Costs FTEs

The Actual Response Surface of System



12-run DoE for Full Quadratic Model



True Response Surface Overlay



Full quadratic fit



Poor fit



Can Solve Some of The Prediction Problem With Space-Filling Designs & Bootstrapping Models like (SVEM)

SVEM fit with SFD



True response surface



Better fit



Self-Validating Ensemble Models

P. Ramsey, M. Gaurdard, Predictum Inc

predictum

Traditional ML Approach

Training Data

One Week to Prepare and Analyze

Validation Data

One Week to Prepare and Analyze

Test Data

One Week to Prepare and Analyze

SVEM-ML Approach



Digital Lab

More data, better insights, efficiency for scientists and clients

Protocols designed in the cloud, from anywhere

e.g. HT cell culture and Protein Purification

Data Integrated from multiple sources

on-line and off-line data, structured, with metadata

Data Served to Modelling Tools at Data Synapses

Markus Gershater

Synthace

Digital Foundation for CGMP Control Strategy

From Vectors to Drug Substance



Predictive Process Modelling

DATAHOW

Data Lake

MVDA (online and offline)

SIMCA

KNIME

KNIME

ELN

Benchling

Historian

OSIsoft.

KNIME

LIMS

charles river

Synthace

KNIME

Synthace

KNIME

KNIME

KNIME

Cell Line Development

Process Development

Analytical Development

Formulation Development

MFG

QC

Digital Twin Development for Automated Process Control

Transposons for Cell Line Development

Oren Beske

ATUM

Receipt of DNA to release of tox supplies
18 months



accelerative actions

7-12 months

Mounting Support in 2010s for a Disruptive CMC Concept



AIChE

Accelerating Patient Access to Novel Biologics Using Stable Pool-Derived Product for Non-Clinical Studies and Single Clone-Derived Product for Clinical Studies

Trent P. Munro
Attribute Sciences, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320
Kim Le
Drug Substance Technologies, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320
Huong Le
Drug Substance Technologies, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320
Li Zhang
Drug Substance Technologies, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320
Jennitte Stevens
Drug Substance Technologies, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320
Neil Soice
Drug Substance Technologies, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320
Sabrina A. Benchaar
Attribute Sciences, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320
Robert W. Hong
Attribute Sciences, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320
Chetan T. Goudar
Drug Substance Technologies, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320

Available online at www.sciencedirect.com
ScienceDirect
Current Opinion in Chemical Engineering
ELSEVIER

Beyond preclinical research: production of CHO-derived biotherapeutics for toxicology and early-phase trials by transient gene expression or stable pools

Matthew Stuible[1], Frank van Lier[1], Matthew S Croughan[2] and Yves Durocher[1]

Leap-In Transposase® Platform (ATUM)

Reliable, Reproducible, and Representative Cell Substrate (pools and clones)



What Has Changed? Pandemic Allowed for Speed-to-FIH Concepts

REGEN-COV™ Rapid response platform at pandemic speed from REGENERON



More Coming Towards “Max Acceleration”

BI platform for two tiered CLD strategy

8 x 2,000 L Batches with Pool

Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable pool

Valerie Schmieder [a], Juergen Fieder [a], Raphael Drerup [b], Erik Arango Gutierrez [b], Carina Guelch [c], Jessica Stolzenberger [d], Mihaela Stumbaum [e], Volker Steffen Mueller [f], Fabian Higel [f], Martin Bergbauer [g], Kim Bornhoefft [h], Manuel Wittner [i], Petra Gronemeyer [j], Christian Braig [k], Michaela Huber [l], Anita Reisenauer-Schaupp [m], Markus Michael Mueller [n], Mark Schuette [o], Sebastian Puengel [a], Benjamin Lindner [a], Moritz Schmidt [a], Patrick Schulz [a], Simon Fischer [a,*]



Large-scale manufacturing of mAb1 in the 2000 L scale using a stable CHO pool cell line generated via transposase-mediated STI. Viable cell concentration, viability, productivity of 8 x 2000 L scale batches.

Stable Bulk Pools Are Gaining Momentum

Do you use non-clonal lines for tox supply?



Genetic Stability (ref)



Consistent PQs across stable cell line pools stable cell lines (ref)







Wheeler Bio

Capabilities

Wheeler Bio Facilities

Research, development, and clinical manufacture*

Boston Research Center

1,200 sq. ft.

Molecular Biology:	Vector Design, Engineering, and Validation
Transient Expression:	ExpiCHO and Expi293
Stable Cell Line Generation:	Horizon CHOSOURCE™ with TNT Transposon Technology & ATUM Leap-In® Transposon Technology with miCHO™ Cell Line
HTP Protein Sciences:	HTP Protein Expression, Purification, and Analytics
Advanced Expression Systems Engineering:	Proprietary

Oklahoma City Development Center

10,000 sq. ft.

Transient Expression:	ExpiCHO and Expi293
Stable Cell Line Development:	ATUM Leap-In® Transposon Technology with miCHO™ or Horizon CHOSOURCE™ Cell Lines Stable Bulk Cultures (SBC) and Clone Isolation
Process Development:	High Throughput Upstream Cell Culture (optimization, intensification, characterization) & Downstream Purification, Process Dev., Scale-up, and Tech. Transfer
Analytical Development:	High Throughput Protein Analytics supporting PD, Analytical Test Method Dev., Qualification, and Tech. Transfer
Formulation Development:	HighThroughput Formulation Screening and Stability
Preclinical Material Supply:	Standardized Wheeler Process, Analytical, and CoT. From SBCs or Clones. Lead Candidate Selection through Tox

Oklahoma City Manufacturing Center

35,000 sq. ft.

Master Cell Banking:	Two (2) Grade C MCB Suites with Automated Vialing Capabilities
Solution Preparation:	Grade C Solution Prep. Suite with Single-use Mixers for Media and Buffers
Clinical Production Suites:	Two (2) Grade D Ballroom Suites with Fully Closed SUT Process Equipment
QC Testing and Release:	RightSource℠ - For Raw Materials, DS/DP Testing, Stability, and Environment Monitoring

* Launch Q3 2023

Custom Development Services

State-of-the-art CMC development laboratory with well integrated digital solutions

Cell Line Development

Process Development

Analytical Method Development

Formulation Development

Preclinical Material Supply

Clinical Material Supply

Portable CMC™



Reliable, reproducible, & representative materials from standard process supporting four (4) lead molecules

Module	WP	Purpose	Description
Lead Selection	WP 1	Platform access point	DNA to SBC Bank + CQA Test on 4 Lead Molecules
	WP 2	Formulations & Manufacturability	SBC to CPP Test at 10 L on 4 Leads Molecules (Manufacturability)
Clone Selection	WP 3	Single-cell cloning	SBC to SBC-DCB (non-CGMP)
	WP 4	MCB prep from clone	DCB to MCB (CGMP)
	WP 5	Clone stability	MCB to 60+ GEN (Cell Substrate Stability per ICH Q5D)
CDMO Selection	WP 6	Rapid tox materials	SBC/MCB to TOX (40L) (SBC is an accelerated option)
	WP 7	Clinical materials	MCB to RDS (released CGMP drug substance)
	WP 8	Drug product	Managed Outsourcing
	WP 9	Prep for scale-up and TT	RFP and Tech Transfer for Pivotal Trial Material Supply

Portable CMC™ - **Lead Selection** Module

Module	WP	Purpose	Description
Lead Selection	WP 1	Platform access point	DNA to SBC Bank + CQA Test on 4 Lead Molecules
	WP 2	Formulations & Manufacturability	SBC to CPP Test at 10 L on 4 Leads Molecules (Manufacturability)

Prepare Stable Bulk Cultures & Representative Materials With Supporting Analytics For Lead Candidate Selection







Quality Attribute	Product/Process Characteristic	Assay Type
Quantity/Strength	**Amount/Concentration**	Absorbance at 280 nm (A280)
Activity/Identity	**Target Antigen Binding**	Bio-layer Interferometry (BLI)
Quality	**Purity - Size Variants**	Capillary Electrophoresis-SDS (non-reduced/reduced) & Size Exclusion Chromatography (SE-UPLC)
Quality	**Purity - Size Variants**	CE-SDS (reduced)
Quality/ Characterization	**Purity - Charge Heterogeneity**	Capillary Isoelectric Focusing (cIEF)
Characterization	**PTM - N- Glycans**	Labelled, Released N-Glycan Profile by UPLC
Characterization/ Identity	**Primary Structure/ Molecular Weight**	Intact Mass by LC/MS (Non-reduced Glycosylated, Non-reduced De-Glycosylated, Reduced Glycosylated, Reduced De-glycosylated)
Characterization/ Identity	**Primary Structure PTMs**	Peptide Mapping by LC-MS/MS
Stability	**Melting Temperature**	Dynamic Light Scattering (DLS), Static Light Scattering (SLS), Intrinsic Fluorescence
Stability	**Aggregation Temperature**	DLS, SLS, Intrinsic Fluorescence
Safety	**Endotoxin**	Limulus Amebocyte Lysate (LAL)

Verify Process Control & Generate Representative Materials for Preclinical Testing







Upstream In-Process Analytical		Downstream In-Process Analytical	Analytical Certificate of Test	
Titer	pCO_2	Amount/Concentration	Strength – Amount/Concentration	Safety – Residual DNA
Viable Cell Density	pO_2	Purity - Size Variants	Potency – Target Antigen Binding	Safety – Residual HCP
Viability	Sodium	Purity - Residual DNA	Purity – Size Variants	Safety – Residual Protein A
Glucose	Potassium	Purity - Residual HCP	Purity – Charge Heterogeneity	Safety – Endotoxin
Lactate	Calcium	Purity - Residual Protein A	Characterization – Primary Structure/N- Glycans	pH
Glutamine	Osmolarity	Unit Operation Recoveries (Step Yields)	Characterization – Primary Structure PTMs	Conductivity
Glutamate	Bicarbonate	Process Recovery (Overall Yield)	Identity – Primary Structure/Molecular Weight	Appearance
Ammonium	CO_2 Saturation		Identity – Peptide Map Fingerprint	
pH	O_2 Saturation			



Portable CMC™ **Clone Selection** Module

Module	WP	Purpose	Description
Clone Selection	WP 3	Single-cell cloning	SBC to SBC-DCB (non-CGMP)
	WP 4	MCB prep from clone	DCB to MCB (CGMP)
	WP 5	Clone stability	MCB to 60+ GEN (Cell Substrate Stability per ICH Q5D)

WP 3 Single-Cell Cloning

Transposon-based systems drive optimal lead selection & enables reliable, reproducible, representative stable bulk cultures



ATUM

Leap-In®
Transposase

Stable Bulk
Culture
Generation

Clone Isolation
&
Screening

Clone Validation
&
Stability

Cell Sorting, Transfection, and Imaging Technologies

- Wolf® Cell Sorter
- Neon™ Transfection System
- Echo Revolve 4 Upright and Inverted Microscope

Solentim Cell Line Development Ecosystem:

- VIPS™ high efficiency multi-tasking single cell seeder
- Cell Metric® high contrast whole-cell imager
- ICON™ productivity analyzer
- STUIDIUS™ data management system

High-Throughput

- Ambr®15 and Ambr®250
- BioFLO 320 (3cc – 50cc BioBLU vessels)

Process Analytics

- Vi-Cell™ XR Cell Viability Analyzer
- Cedex Bio Analyzer
- Integrated and Standalone BioProfile® FLEX2
- Octet® RH16

Automated Single Cell Isolation, Evidence of Clonality, Titer, Viability, and Productivity Ranking to Select Top Clones

	Q2	Q3	
	Month 6	Month 7	Month 8
Clone Selection WP3			
HTP Clone Isolation			
HTP Clone Validation			
DCB Generation			
DCB Testing			
Clonal Cell Line Development Package			

Automated Evidence of Clonality





Tracking Top Performing Clones During Outgrowth

High Throughput Clone Validation with Bioreactor Process Analytical Monitoring and Productivity Assessment

Ambr®15 Viable Cell Density - Clone Selection
24 Top Clones



Ambr®15 % Viability - Clone Selection
24 Top Clones



Ambr®15 Cumulative Specific Productivity - Clone Selection
24 Top Clones



Ambr®15 Bioreactor Harvest Titer - Clone Selection
24 Top Clones



Master Cell Bank (CGMP) Generation, Characterization, and Release



Automated Master Cell Bank Vialing

Two (2) Grade C Master Cell Banking Suites



Master Cell Bank (CGMP) Cell Substrate Stability 60 Generations per ICH Q5D



Portable CMC™ **CDMO Selection** Module

Module	WP	Purpose	Description
CDMO Selection	**WP 6**	**Rapid tox materials**	**SBC/MCB to TOX (40L) (SBC is an accelerated option)**
	WP 7	Clinical materials	MCB to RDS (released CGMP drug substance)
	WP 8	Drug product	Outsourcing partner
	WP 9	Prep for scale-up and TT	RFP and Tech Transfer for Pivotal Trial Material Supply

Use of Stable Bulk Cultures Accelerates the Timeline to Initiate Toxicology Studies By 3 Months

SBC to Tox



MCB to Tox



Summary of Wheeler Bio

Solving for Translation	• Agile, boutique CMC development business embedded in venture studio
Experienced Leadership	• Seasoned development team with CMC and regulatory experience
Aligned Culture	• Every employee is a shareholder with shared vision, mission, and core values • Purpose-built business to solve for customer experience
Technology Stacked	• Leap-In Transposase® CLD Platform • Synthace® Experiment Platform • Ambr® 250 Digital Twin (DataHowLab) • DynaDrive Single-Use Bioreactors (ThermoFisher)
Compressed Workflow	• CRO Integration • Portable CMC™ Platform • RightSource™ Insourcing QC Solution

Wheeler Bio

Please direct all inquiries to: bd@wheelerbio.com or:

Jesse D. McCool, Ph.D.
Co-Founder and Chief Executive Officer
Email Jesse.McCool@wheelerbio.com

David Schmidt, M.Sc., MBA
Vice President of Business Operations
Email David.Schmidt@wheelerbio.com

Brian Berquist, Ph.D.
Sr. Vice President and Chief Development Officer
Email Brian.Berquist@wheelerbio.com

Thank you!